In vitro activity of levonadifloxacin, the active drug of orally administered prodrug alalevonadifloxacin against bloodstream isolates of Burkholderia pseudomallei
Clinical Epidemiology and Global Health(2024)
摘要
Background and objective
Eradication of Burkholderia pseudomallei infections requires prolonged antibiotic treatment indicating microbiological and pharmacokinetic limitations of current options.
Methods and results
Levonadifloxacin, a novel benzoquinolizine-fluoroquinolone available intravenously and orally, showed greater activity than ciprofloxacin (MICs, 0.25 to 2 versus 0.25–8 mg/L) and comparable to doxycycline against 50 B. pseudomallei isolates. In time-kill assay, levonadifloxacin exerted rapid ∼3 log10 reduction while doxycycline was bacteriostatic.
Conclusion
Levonadifloxacin merits further investigations as a potential treatment option for B. pseudomallei infections.
更多查看译文
关键词
Melioidosis,Burkholderia pseudomallei,Levonadifloxacin,Alalevonadifloxacin,Bactericidal
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要